Biogen [BIIB] vs Pfizer [PFE] Detailed Stock Comparison
Biogen
NASDAQ
Loading...
Pfizer
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Biogen wins in 11 metrics, Pfizer wins in 8 metrics, with 0 ties. Biogen appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Biogen | Pfizer | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 15.30 | 14.48 | Pfizer |
| Price-to-Book Ratio | 1.33 | 1.75 | Biogen |
| Debt-to-Equity Ratio | 37.40 | 69.70 | Biogen |
| PEG Ratio | 1.92 | 0.00 | Pfizer |
| EV/EBITDA | 8.47 | 8.35 | Pfizer |
| Profit Margin (TTM) | 15.31% | 16.84% | Pfizer |
| Operating Margin (TTM) | 34.61% | 28.68% | Biogen |
| EBITDA Margin (TTM) | 34.61% | 28.68% | Biogen |
| Return on Equity | 9.13% | 12.17% | Pfizer |
| Return on Assets (TTM) | 5.62% | 5.25% | Biogen |
| Free Cash Flow (TTM) | $2.52B | $9.84B | Pfizer |
| Dividend Yield | N/A | 5.32% | N/A |
| 1-Year Return | -13.89% | -4.23% | Pfizer |
| Price-to-Sales Ratio (TTM) | 2.34 | 2.44 | Biogen |
| Enterprise Value | $27.28B | $204.73B | Pfizer |
| EV/Revenue Ratio | 2.73 | 3.21 | Biogen |
| Gross Profit Margin (TTM) | 77.13% | 74.22% | Biogen |
| Revenue per Share (TTM) | $68 | $11 | Biogen |
| Earnings per Share (Diluted) | $10.45 | $1.89 | Biogen |
| Beta (Stock Volatility) | 0.13 | 0.47 | Biogen |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Biogen vs Pfizer Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Biogen | -3.65% | 16.39% | 12.89% | 20.33% | 22.32% | 6.59% |
| Pfizer | -3.43% | 15.19% | 10.41% | 7.84% | 12.68% | 2.86% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Biogen | -13.89% | -38.00% | -44.20% | -40.60% | 177.62% | 323.97% |
| Pfizer | -4.23% | -35.33% | -21.60% | -13.22% | 65.18% | 18.28% |
News Based Sentiment: Biogen vs Pfizer
Biogen
News based Sentiment: POSITIVE
October proved to be a pivotal month for Biogen, driven by the promising Phase III results for Lecanemab, a potential blockbuster Alzheimer's drug. This, combined with strategic partnerships, regulatory approvals, and strong financial performance, significantly strengthens the company's long-term outlook and justifies a positive investment sentiment.
Pfizer
News based Sentiment: POSITIVE
Pfizer had a strong month driven by a significant agreement with the Trump Administration that lowered tariff risks and unlocked substantial investment. This, coupled with positive analyst reactions and a notable stock price increase, signals a positive shift in investor sentiment and strengthens the company's long-term outlook.
Performance & Financial Health Analysis: Biogen vs Pfizer
| Metric | BIIB | PFE |
|---|---|---|
| Market Information | ||
| Market Cap | $23.44B | $158.84B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,927,000 | 73,207,865 |
| 90 Day Avg. Volume | 1,761,453 | 53,889,402 |
| Last Close | $154.05 | $26.43 |
| 52 Week Range | $110.04 - $194.13 | $20.92 - $30.43 |
| % from 52W High | -20.65% | -13.14% |
| All-Time High | $480.18 (Mar 16, 2015) | $61.71 (Dec 20, 2021) |
| % from All-Time High | -67.92% | -57.17% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.07% | 0.10% |
| Quarterly Earnings Growth | 0.09% | 69.98% |
| Financial Health | ||
| Profit Margin (TTM) | 0.15% | 0.17% |
| Operating Margin (TTM) | 0.35% | 0.29% |
| Return on Equity (TTM) | 0.09% | 0.12% |
| Debt to Equity (MRQ) | 37.40 | 69.70 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $120.29 | $15.60 |
| Cash per Share (MRQ) | $18.82 | $2.33 |
| Operating Cash Flow (TTM) | $2.12B | $15.19B |
| Levered Free Cash Flow (TTM) | $2.27B | $16.02B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 5.32% |
| Last 12-Month Dividend | N/A | $1.27 |
Valuation & Enterprise Metrics Analysis: Biogen vs Pfizer
| Metric | BIIB | PFE |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 15.30 | 14.48 |
| Forward P/E | 9.60 | 9.34 |
| PEG Ratio | 1.92 | 0.00 |
| Price to Sales (TTM) | 2.34 | 2.44 |
| Price to Book (MRQ) | 1.33 | 1.75 |
| Market Capitalization | ||
| Market Capitalization | $23.44B | $158.84B |
| Enterprise Value | $27.28B | $204.73B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.73 | 3.21 |
| Enterprise to EBITDA | 8.47 | 8.35 |
| Risk & Other Metrics | ||
| Beta | 0.13 | 0.47 |
| Book Value per Share (MRQ) | $120.29 | $15.60 |
Financial Statements Comparison: Biogen vs Pfizer
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BIIB | PFE |
|---|---|---|
| Revenue/Sales | $2.43B | $14.65B |
| Cost of Goods Sold | $629.30M | $3.78B |
| Gross Profit | $1.80B | $10.88B |
| Research & Development | $434.10M | $2.48B |
| Operating Income (EBIT) | $625.20M | $3.77B |
| EBITDA | $831.80M | $5.75B |
| Pre-Tax Income | $311.20M | $3.04B |
| Income Tax | $70.70M | $141.00M |
| Net Income (Profit) | $240.50M | $2.93B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BIIB | PFE |
|---|---|---|
| Cash & Equivalents | $2.60B | $1.43B |
| Total Current Assets | $7.63B | $45.86B |
| Total Current Liabilities | $5.30B | $36.45B |
| Long-Term Debt | $4.87B | $56.82B |
| Total Shareholders Equity | $16.98B | $90.64B |
| Retained Earnings | $19.50B | $119.59B |
| Property, Plant & Equipment | $6.22B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BIIB | PFE |
|---|---|---|
| Operating Cash Flow | $518.90M | $3.91B |
| Capital Expenditures | $-37.10M | $-564.00M |
| Free Cash Flow | $212.20M | $1.77B |
| Debt Repayment | $0 | $-2.43B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BIIB | PFE |
|---|---|---|
| Shares Short | 5.13M | 112.93M |
| Short Ratio | 3.35 | 2.85 |
| Short % of Float | 0.05% | 0.02% |
| Average Daily Volume (10 Day) | 1,927,000 | 73,207,865 |
| Average Daily Volume (90 Day) | 1,761,453 | 53,889,402 |
| Shares Outstanding | 145.72M | 5.67B |
| Float Shares | 146.23M | 5.68B |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.93% | 0.67% |
Dividend Analysis & Yield Comparison: Biogen vs Pfizer
| Metric | BIIB | PFE |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.27 |
| Last 12-Month Dividend Yield | N/A | 5.32% |
| 3-Year Avg Annual Dividend | N/A | $1.52 |
| 3-Year Avg Dividend Yield | N/A | 1.27% |
| 3-Year Total Dividends | N/A | $4.55 |
| Ex-Dividend Date | N/A | Jan 24, 2025 |